Vaxcyte Past Earnings Performance

Past criteria checks 0/6

Vaxcyte's earnings have been declining at an average annual rate of -47.2%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-47.2%

Earnings growth rate

28.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-14.9%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vaxcyte makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:5VA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-50882447
30 Jun 240-49774428
31 Mar 240-43767369
31 Dec 230-40261332
30 Sep 230-30055280
30 Jun 230-26550230
31 Mar 230-24545196
31 Dec 220-22340169
30 Sep 220-17435141
30 Jun 220-14330114
31 Mar 220-1182793
31 Dec 210-1002578
30 Sep 210-922370
30 Jun 210-872266
31 Mar 210-831967
31 Dec 200-891674
30 Sep 200-831472
30 Jun 200-731166
31 Mar 200-641157
31 Dec 190-50946
31 Dec 180-29530

Quality Earnings: 5VA is currently unprofitable.

Growing Profit Margin: 5VA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5VA is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.

Accelerating Growth: Unable to compare 5VA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5VA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 5VA has a negative Return on Equity (-14.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/04 06:08
End of Day Share Price 2024/09/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vaxcyte, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Thomas ShraderBTIG
Louise ChenCantor Fitzgerald & Co.